TScan Therapeutics
Update in progressTCRX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
TScan Therapeutics is a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its lead candidate, TSC‑101, targets AML, MDS, and ALL in patients undergoing allogeneic hematopoietic cell transplantation and is in Phase I. It also develops allogeneic TCR-T programs (TSC‑102‑A01/A03) and solid-tumor programs (TSC‑200 to ‑204). It has an Amgen collaboration on Crohn’s disease antigens. Founded 2018, in Waltham, MA.
Company score
- Sentiment
- 0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.10
- Governance
- -0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!